RxDoctor Payments Data

James Volpe, DO

Family Medicine · Philadelphia, PANPI 1336188689

Payments from drug & device makers

$803in general payments, 2019–2025

Across 60 payments — averaging $13.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$339
  • AstraZeneca$120
  • Novo Nordisk$100
  • Astellas Pharma US Inc$59
  • GSK$46
  • Galderma Laboratories, L.p.$44
  • plus $94 from 4 others

What the payments were for

  • Food & beverage$803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$803 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$236,864
Medicare patients
383
Services billed
2,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$61,694
OzempicSemaglutide40$56,574
AbrysvoRsv Vacc, Pref A And Pref B/Pf34$9,535
MyrbetriqMirabegron25$8,270
Pantoprazole Sodium105$5,912
ArexvyRsvpref3 Antigen/As01e/Pf20$5,809
ShingrixVaricella-Zoster Ge/As01b/Pf28$5,625
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl68$4,667
Amiodarone Hcl37$4,026
Atorvastatin Calcium291$3,989
Duloxetine Hcl56$3,480
Novolog FlexpenInsulin Aspart12$3,110
Tolterodine Tartrate ErTolterodine Tartrate17$2,661
Sevelamer Carbonate17$2,620
Omeprazole203$2,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$100$56,57440 claims
GSKArexvy, Shingrix$46$11,43448 claims
Astellas Pharma US IncMyrbetriq$59$8,27025 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$16$4,66768 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →